Bath Savings Trust Co Has $1.13 Million Position in Novo Nordisk A/S (NYSE:NVO)

Bath Savings Trust Co lowered its position in Novo Nordisk A/S (NYSE:NVOFree Report) by 1.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,964 shares of the company’s stock after selling 163 shares during the quarter. Bath Savings Trust Co’s holdings in Novo Nordisk A/S were worth $1,134,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Westside Investment Management Inc. lifted its stake in Novo Nordisk A/S by 83.3% in the third quarter. Westside Investment Management Inc. now owns 1,428 shares of the company’s stock valued at $130,000 after acquiring an additional 649 shares during the last quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth about $2,408,000. Lazard Asset Management LLC lifted its stake in shares of Novo Nordisk A/S by 182.2% during the 3rd quarter. Lazard Asset Management LLC now owns 1,494,214 shares of the company’s stock worth $135,883,000 after buying an additional 964,640 shares during the last quarter. Benedict Financial Advisors Inc. lifted its stake in shares of Novo Nordisk A/S by 94.0% during the 3rd quarter. Benedict Financial Advisors Inc. now owns 44,292 shares of the company’s stock worth $4,028,000 after buying an additional 21,457 shares during the last quarter. Finally, CENTRAL TRUST Co lifted its stake in shares of Novo Nordisk A/S by 111.6% during the 3rd quarter. CENTRAL TRUST Co now owns 6,004 shares of the company’s stock worth $546,000 after buying an additional 3,166 shares during the last quarter. Institutional investors and hedge funds own 6.41% of the company’s stock.

Novo Nordisk A/S Price Performance

NVO stock opened at $132.37 on Friday. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.19. Novo Nordisk A/S has a 12 month low of $67.66 and a 12 month high of $138.28. The firm has a market cap of $594.01 billion, a P/E ratio of 48.94, a P/E/G ratio of 2.20 and a beta of 0.41. The company’s 50-day moving average price is $118.09 and its two-hundred day moving average price is $99.78.

Novo Nordisk A/S (NYSE:NVOGet Free Report) last released its earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The firm had revenue of $9.51 billion for the quarter, compared to analyst estimates of $9.14 billion. On average, analysts anticipate that Novo Nordisk A/S will post 3.36 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a Semi-Annual dividend, which will be paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th will be issued a $0.664 dividend. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. This represents a yield of 0.9%. The ex-dividend date is Friday, March 22nd. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 22.92%.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 target price for the company. TD Cowen raised their target price on shares of Novo Nordisk A/S from $105.00 to $115.00 and gave the stock an “outperform” rating in a research note on Monday, December 4th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $140.00 price objective on shares of Novo Nordisk A/S in a research note on Tuesday, February 20th. Finally, UBS Group assumed coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 16th. They issued a “neutral” rating for the company. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $121.25.

Check Out Our Latest Stock Analysis on Novo Nordisk A/S

Novo Nordisk A/S Company Profile

(Free Report)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

See Also

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.